Key considerations during the transition from the acute phase of the COVID-19 pandemic: a narrative review
P Rzymski, M Pokorska-Śpiewak, T Jackowska… - Vaccines, 2023 - mdpi.com
The COVID-19 pandemic has been met with an unprecedented response from the scientific
community, leading to the development, investigation, and authorization of vaccines and …
community, leading to the development, investigation, and authorization of vaccines and …
Third BNT162b2 vaccination neutralization of SARS-CoV-2 Omicron infection
I Nemet, L Kliker, Y Lustig, N Zuckerman… - … England Journal of …, 2022 - Mass Medical Soc
Neutralization of Omicron with Third Vaccine Dose Serum samples from 20 participants who
had received two doses of the BNT162b2 vaccine and from 20 who had received three …
had received two doses of the BNT162b2 vaccine and from 20 who had received three …
COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study
Background With the surge of new SARS-CoV-2 variants, countries have begun offering
COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult …
COVID-19 vaccine booster doses to high-risk groups and, more recently, to the adult …
Public health impact of covid-19 vaccines in the US: observational study
Objective To evaluate the impact of vaccine scale-up on population level covid-19 mortality
and incidence in the United States. Design Observational study. Setting US county level …
and incidence in the United States. Design Observational study. Setting US county level …
Effectiveness of a third dose of BNT162b2 mRNA COVID-19 vaccine in a large US health system: a retrospective cohort study
SY Tartof, JM Slezak, L Puzniak, V Hong… - The Lancet Regional …, 2022 - thelancet.com
Background Globally, recommendations are expanding for third (booster) doses of
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …
BNT162b2 (Pfizer–BioNTech). In the United States, as of November 19, 2021, boosters were …
The Impact of Vaccination on COVID-19 Burden of Disease in the Adult and Elderly Population: A Systematic Review of Italian Evidence
GE Calabrò, C Pappalardo, F D'Ambrosio, M Vece… - Vaccines, 2023 - mdpi.com
COVID-19 is a major global health threat, with millions of confirmed cases and deaths
worldwide. Containment and mitigation strategies, including vaccination, have been …
worldwide. Containment and mitigation strategies, including vaccination, have been …
COVID-19 vaccine boosters: the good, the bad, and the ugly
Pursuing vaccinations against COVID-19 brings hope to limit the spread of SARS-CoV-2
and remains the most rational decision under pandemic conditions. However, it does not …
and remains the most rational decision under pandemic conditions. However, it does not …
Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 …
F Chiuppesi, JA Zaia, PH Frankel, R Stan… - The Lancet …, 2022 - thelancet.com
Background COH04S1, a synthetic attenuated modified vaccinia virus Ankara vector co-
expressing SARS-CoV-2 spike and nucleocapsid antigens, was tested for safety and …
expressing SARS-CoV-2 spike and nucleocapsid antigens, was tested for safety and …
Number of averted COVID-19 cases and deaths attributable to reduced risk in vaccinated individuals in Japan
Summary Background In Japan, vaccination against severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) was initiated on 17 February 2021, mainly using messenger …
coronavirus 2 (SARS-CoV-2) was initiated on 17 February 2021, mainly using messenger …
SARS-CoV-2 antibodies and breakthrough infections in the Virus Watch cohort
A range of studies globally demonstrate that the effectiveness of SARS-CoV-2 vaccines
wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection …
wane over time, but the total effect of anti-S antibody levels on risk of SARS-CoV-2 infection …